Clinical Publications
May 8, 2017

The Lancet Oncology

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Learn More
October 12, 2016


A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma

Learn More
October 15, 2014

Clinical Cancer Research

A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent,CPI-613, in Patients with Advanced
Hematologic Malignancies

Learn More
Non-Clinical Publications
March 10, 2014

Cancer and Metabolism

A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process

Learn More